Antengene has received the go ahead from the Bellberry Human Research Ethics Committee (HREC) in Australia to commence the Phase I STAMINA trial of the company’s ATG-037 to treat locally advanced or metastatic solid tumour patients.
ATG-037 is an oral, small-molecule inhibitor of the cluster of differentiation 73 (CD73). CD73 produces adenosine, which causes immunosuppression in the microenvironment of the tumour.
Go deeper with GlobalData
The primary goal of this first-in-human trial is to analyse the safety, tolerability and initial efficacy of ATG-037 as a single agent or along with an immune checkpoint inhibitor (CPI) in individuals with locally advanced or metastatic solid tumours.
This will aid in determining a suitable dose of ATG-037 for Phase II trials.
Furthermore, the trial will analyse the pharmacology of the therapy as the secondary goal.
Antengene chief medical officer Kevin Lynch said: “Preclinical toxicology data suggests that ATG-037 will have a broad therapeutic window and further preclinical data suggests the potential for differentiated characteristics compared to other CD73 inhibitors.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“ATG-037 also has the potential to be used in combination with several agents in the Antengene pipeline including ATG-101, a proprietary PD-L1/4-1BB bispecific antibody, demonstrating the in-house combinatory potential of our pipeline programmes.”
In preclinical studies, ATG-037 showed to defeat the ‘hook effect’ usually associated with anti-CD73 antibodies and demonstrated to have a wider therapeutic window in GLP toxicology studies.
The company dosed the first subject in the Phase I PROBE trial of ATG-101 in metastatic/advanced solid tumour and B-cell non-Hodgkin’s lymphoma (B-NHL) patients in Australia, in December last year.
